Merck's Victrelis Hepatitis C Drug Will Be Off the Market in the US

Merck this week notified the FDA that it will stop selling its Victrelis medicine in the US by the end of this year, although the drug will remain available in other countries.

Rival hepatitis C drugs from Merck and Vertex Pharmaceuticals made a big splash when they debuted in 2011, marking an advance in treatment of the liver disease and a lucrative new market segment. But now the Class of 2011 has almost sunk to the bottom, made obsolete by a newer wave of drugs, a sign of how rapidly the hepatitis C market is changing.

Merck this week notified the FDA that it will stop selling its Victrelis medicine in the US by the end of this year, although the drug will remain available in other countries. The move comes 3 months after Vertex Pharmaceuticals discontinued US sales of its own Incivek hepatitis C drug.

Read more: http://on.wsj.com/1xYmX3N

Source: Wall Street Journal